PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10571991
Filing Date	2006-03-15
First Named Inventor	Bernard Barlaam
Art Unit	1624
Examiner Name	Douglas M. Willis
Attorney Docket Number	09963.0008

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5576322		1996-11-19	Takase et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040053972	A1	2004-03-18	Nara et al.	
	2	20040192664	A1	2004-09-30	Kunz et al.	
	3	20040198997	A1	2004-10-07	Scholz et al.	
	4	20050130995	A1	2005-06-16	Nishino et al.	
	5	20050148607	A1	2005-07-07	Suzuki et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

	6	20060167026	A1	2006-07-27	Nawa et al.	
	7	20060188501	A1	2006-08-24	Homma et al.	
	8	20090312313	A1	2009-12-17	Shimizu et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2001/19788	WO	A2	2001-03-22	COR Therapeutics, Inc.	(Submitted in 3 parts)	☐
	2	2001/21160	WO	A2	2001-03-29	Axxima Pharmaceuticals Aktiengesellschaft		☐
	3	2001/32155	WO	A2	2001-05-10	The University of Manchester		☐
	4	2001/64642	WO	A2	2001-09-07	COR Therapeutics, Inc.	(Submitted in 3 parts)	☐
	5	2002/05791	WO	A2	2002-01-24	Pharmacia & Upjohn S.P.A.		☐
	6	2002/17712	WO	A2	2002-03-07	FMC Corporation	(Submitted in 2 parts)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

	7	2002/20020	WO	A1	2002-03-14	Pharmacia & Upjohn, S.P.A.		☐
	8	2002/30358	WO	A2	2002-04-18	Tularik, Inc.		☐
	9	2003/031406	WO	A2	2003-04-17	IRM LLC		☐
	10	2003/097086	WO	A2	2003-11-27	Technische Universitat Munchen	(Submitted in 2 parts)	☐
	11	2003/097615	WO	A1	2003-11-27	Scios, Inc.	(Submitted in 2 parts)	☐
	12	2003/099276	WO	A1	2003-12-04	Bristol-Myers Squibb Company	(Submitted in 7 parts)	☐
	13	2004/010929	WO	A2	2004-02-05	Scios, Inc.		☐
	14	2004/072038	WO	A1	2004-08-26	Vertex Pharmaceuticals, Inc.		☐
	15	2004/085385	WO	A2	2004-10-07	Schering Corporation		☐
	16	2004/096224	WO	A2	2004-11-11	Boehringer Ingelheim International GmbH		☐
	17	2005/001053	WO	A2	2005-01-06	Waksal et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

	18	2005/003325	WO	A2	2005-01-13	Dana Farber Cancer Institute		☐
	19	2005/016347	WO	A1	2005-02-24	Pfizer Products, Inc.		☐
	20	2005/030140	WO	A2	2005-04-07	Ex-Elixis, Inc.	(Submitted in 4 parts)	☐
	21	2000/72849	WO	A1	2000-12-07	Hadasit Medical Research Services and Development		☐
	22	2003246780	JP	A	2003-09-02	Eisai	English Translation of Abstract from Japanese Patent Office	☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ALFEREZ ET AL. "Inhibiting Signaling by erbB Receptor Tyrosine Kinases with AZD8931, a Potent Reversible small Molecule Inhibitor, Reduces Intestinal Adenoma Formation in the ApcMin/+ Mouse Model". EORTC-NCI-AACR (2010), Abstract 471	☐
	2	ALFEREZ ET AL. "Inhibiting Signaling by erbB Receptor Tyrosine Kinases with AZD8931, a Potent Reversible small Molecule Inhibitor, Reduces Intestinal Adenoma Formation in the ApcMin/+ Mouse Model". EORTC-NCI-AACR (2010), Poster	☐
	3	BLOWERS "AZD8931". IASLC ANNUAL TARGETED THERAPIES OF THE TREATMENT OF LUNG CANCER MEETING (2011), Santa Monica, CA, PowerPoint Presentation	☐
	4	CRISTOFANILLI ET AL. "Exploratory Subset Analysis According to Prior Endocrine Treatment of Two Randomized Phase II Trials Comparing Gefitinib (G) with Placebo (P) in Combination with Tamoxifen (T) or Anastrozole (A) in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC)". J CLIN ONCOL. (2009), Vol 27, 15s, Abstract 1014	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

	5	HICKINSON ET AL. "AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2) and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer". CLIN. CANCER RES. (2010), Vol. 16, No. 4, 1159-1169	☐
	6	KEILHOLZ ET AL. "Phase I Dose-Finding Study of Monotherapy with AZD8931, an Inhibitor of erbB1, 2 and 3 Signaling, in Patients with Advanced Solid Tumors". J CLIN ONCOL. (2011), Vol. 29, Abstract 3097	☐
	7	KEILHOLZ ET AL. "Phase I Dose-Finding Study of Monotherapy with AZD8931, an Inhibitor of erbB1, 2 and 3 Signaling, in Patients with Advanced Solid Tumors". ASCO (2011), Poster	☐
	8	KLINOWSKA ET AL. "AZD8931, an Equipotent, Reversible Inhibitor of erbB1, erbB2 and erbB3 Receptor Signaling: Characterisation of Pharmacological Profile". EUROPEAN JOURNAL OF CANCER SUPPLEMENTS (2009), Vol. 7, No. 2, 127	☐
	9	LOPEZ-MARTIN ET AL. "Phase I Dose-Finding Study of AZD8931, an Inhibitor of erbB1, 2 and 3 Receptor Signaling, in Combination with Paclitaxel". J CLIN. ONCOL. (2011), Vol. 29, Abstract 3105	☐
	10	LOPEZ-MARTIN ET AL. "Phase I Dose-Finding Study of AZD8931, an Inhibitor of erbB1, 2 and 3 Receptor Signaling, in Combination with Paclitaxel". ASCO (2011), Poster	☐
	11	MARSHALL ET AL. "Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2 and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 Expression". SABCS (2009), Abstract 5059	☐
	12	NORMANNO ET AL. "Target-based therapies in breast cancer: current status and future perspectives". ENDOCR RELAT CANCER (2009), Vol. 16(3): 675-702	☐
	13	SPEAKE ET AL. "Characterization of AZD8931, a Potent Reversible Small Molecule Inhibitor Against Epidermal Growth Factor Receptor (EGFR), Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) and 3 (HER3) with a Unique and Balanced Pharmacological Profile". J CLIN. ONCOL. (2009), Vol. 27, 15s, Abstract 11072	☐
	14	United States Court of Appeals for the Federal Circuit, Genetics Institute, LLC v. Novartis Vaccines and Diagnostics, Inc., 2010-124; Appeal from the USDC for the District of Delaware in Case No. 08-CV-0290, Judge Sue L. Robinson, Decided August 23, 2011	☐
If you wish to add additional non-patent literature document citation information please click the Add button Add			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10571991
Filing Date	2006-03-15
First Named Inventor	Bernard Barlaam
Art Unit	1624
Examiner Name	Douglas M. Willis
Attorney Docket Number	09963.0008

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robert N.Young/	Date (YYYY-MM-DD)	2011-09-15
Name/Print	Robert N. Young	Registration Number	48412

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.